With the idea of combining one plus one to obtain four, we investigated the potential of an original combination of the thymidine phosphorylase (TYMP) inhibitor tipiracil hydrochloride (TPI) and TLR7 agonist (imiquimod)-activated DC therapy in a CT26 syngeneic immunocompetent colorectal cancer mouse model CT-26 tumors (microsatellite stable, MSI-L, and Kras-mutant) (33), compared them with those treated with monotherapies and healthy individuals, and performed integrated analysis of immune features. This evidence concerns the gene KRAS and colorectal cancer.